Connect with us

Legal & Regulation

M3 Ventures Cannabis Company Fined $50,000 By Massachusetts Regulators Over Pesticide Use

Denis

Published

on

M3 Ventures Cannabis Company Fined $50,000 By Massachusetts Regulators Over Pesticide Use

M3 Ventures, a Plymouth-based cannabis company, is set to pay a $50,000 fine for giving false information about their pesticide use.

According to a MassLive report, an M3 Ventures employee lied to the Massachusetts Cannabis Control Commission about the pesticides the company used to cultivate cannabis. However, Commission chairman Steven Hoffman said that M3 Ventures has “rectified” the issue in a number of ways.

Initially, state inspectors had shut down the company’s dispensaries in Mashpee and Plymouth in December over their pesticide use, but permitted them to reopen in April.

Inspectors found out the prohibited pesticides at the cultivation facility of M3 in November and interviewed the cultivation director about its use. During the following month’s inspection, the company brass admitted that the use of pesticides had been misrepresented by the cultivation director, hence causing closure and fines.

As a result, the company split the position of cultivator director into two – master grower and cultivation operations manager. M3 also partnered with a national firm to help them in developing a plan for cannabis pest management through the use of approved substances.

On top of the fine, the company was put on administrative probation until the end of the year, and has been required to track and record its use of additives daily.

During a press meeting on Thursday, Paul Payer, cannabis control commission enforcement course, said that M3 has not violated any state regulations from the time it reopened, and that the company had taken further steps to comply with the settlement which reflects integrity required by regulators when licensing candidates.

In March, state regulators carried out investigations into two other cannabis companies – acreage holdings and Sea Hunter Therapeutics – to see whether they flouted company ownership rules through using the state regulations’ loopholes to hide their affiliations through using shell companies. This case is still going on.

Denis is one of the most experienced researchers for reviews we have with years of experience in writing about CBD products. He will be one of the most viewed authors due to his own thrill in sharing what he is learning about cannabidiol and supplement use. With a goal of providing clarity within the budding CBD oil industry, Denis will be spending much of the year going through a catalogue of cannabis oil companies in the near future.

Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement

Join Us On Facebook

Advertisement

Trending CBD News

TimesofCBD always fact checks sources and aims for the best accuracy in the reporting curated cannabis content consisting of the latest CBD news, user guides and product health research. Quality is the priority, but we are not eligible to be liable as everything here is for educational, informational purposes only. Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.

What Is CBD?

Advertisement